Previously recorded as 3-V Biosciences, Inc. (to 2020)
14 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2032
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2032 · High confidence
Also notable
Ends Mar 2036 · High confidence
Also notable
Ends May 2032 · High confidence
Also notable
Ends Sep 2035 · High confidence
Also notable
Ends no later than Jun 2044 · Low confidence
Heterocyclic Modulators of Lipid Synthesis
US 8,871,790
The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2014 in our data. Protection runs to 2032.
Heterocyclic Modulators of Lipid Synthesis
US 10,189,822
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Heterocyclic Modulators of Lipid Synthesis and Combinations Thereof
US 10,226,449
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Fatty Acid Synthase Inhibitor for Use in the Treatment of Drug Resistant Cancer
US 10,363,249
Granted 2019. Computed term ends 2035.
Combination Therapies of Fasn Inhibitors with Thyroid Hormone Receptor Agonists
US 12,746,242
Granted 2026. Too new for citation comparison; protection runs to 2044. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Fatty Acid Synthase Inhibitor for Use in the Treatment of Drug Resistant Cancer (US 10,363,249) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 22, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Heterocyclic Modulators of Lipid Synthesis (2012) | 10 in force | to Jan 2035 |
| Combination Therapies of Fasn Inhibitors with Thyroid Hormone Receptor Agonists | 1 in force | to Jun 2044 |
| Heterocyclic Modulators of Lipid Synthesis (2017) | 1 in force | to Mar 2036 |
| Fatty Acid Synthase Inhibitor for Use in the Treatment of Drug Resistant Cancer | 1 in force | to Sep 2035 |
| Heterocyclic Modulators of Lipid Synthesis and Combinations Thereof | 1 in force | to May 2032 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,624,173 | Heterocyclic Modulators of Lipid Synthesis In force · High confidence | In force | High confidence | |
| US 9,809,591 | Heterocyclic Modulators of Lipid Synthesis In force · High confidence | In force | High confidence | |
| US 11,034,690 | Heterocyclic Modulators of Lipid Synthesis In force · Medium confidence | In force | Medium confidence | |
| US 12,551,490 | Heterocyclic Modulators of Lipid Synthesis In force · Medium confidence | In force | Medium confidence | |
| US 8,871,790 | Heterocyclic Modulators of Lipid Synthesis In force · High confidence | In force | High confidence | |
| US 9,428,502 | Heterocyclic Modulators of Lipid Synthesis In force · Low confidence | In force | Low confidence | |
| US 10,226,449 | Heterocyclic Modulators of Lipid Synthesis and Combinations Thereof In force · High confidence | In force | High confidence | |
| US 11,622,968 | Heterocyclic Modulators of Lipid Synthesis In force · High confidence | In force | High confidence | |
| US 10,118,913 | Heterocyclic Modulators of Lipid Synthesis In force · High confidence | In force | High confidence | |
| US 10,053,450 | Heterocyclic Modulators of Lipid Synthesis In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 14: 7 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.